Yazılar

HealthTap partners with Eli Lilly to expand online diabetes care

/in /tarafından

HealthTap, a U.S. telehealth provider, will join Eli Lilly’s digital healthcare platform LillyDirect to deliver virtual diabetes management services nationwide. The collaboration will give diabetic patients direct access to HealthTap’s primary care physicians, who will oversee treatment, lab reviews, and preventive care tailored to each patient’s needs.

HealthTap’s care model emphasizes continuity with one doctor, allowing long-term, personalized management of chronic conditions like diabetes. CEO Sean Mehra said the partnership leverages Lilly’s growing online presence: “As Lilly markets its website as a destination for consumers, we get to tap into it in a very relevant way.”

The move comes amid surging demand for GLP-1 diabetes and obesity drugs, a market dominated by Lilly and Novo Nordisk. Telehealth providers, pharmacies, and pharmaceutical firms are increasingly teaming up to offer direct-to-consumer digital health services.

Earlier this year, primary care firm knownwell joined LillyDirect to offer similar weight and metabolic health programs. Lilly has also broadened the platform to include telehealth partners for Alzheimer’s care, signaling its ambition to build a one-stop digital health ecosystem.

By joining LillyDirect, HealthTap strengthens its foothold in the rapidly expanding telemedicine and chronic disease management market, as patients increasingly seek accessible, ongoing digital care options.

Former X CEO Linda Yaccarino Takes Helm at GLP-1 Telehealth Startup eMed

/in /tarafından

Linda Yaccarino, who recently stepped down as CEO of social media platform X, has been appointed CEO of eMed Population Health, a Miami-based telehealth startup focused on GLP-1 weight loss drugs.

Yaccarino, known for her extensive advertising and digital revenue expertise, led X through a challenging period marked by advertiser skepticism amid controversial content under Elon Musk’s ownership. She previously modernized NBCUniversal’s global advertising business over a decade.

“I brought X through a tremendous growth trajectory, and I’m proud of what we accomplished,” Yaccarino said in a Reuters interview. “Now, it’s the perfect time for a new challenge.”

Founded in 2020, eMed partners with employers and government payers to manage the use of GLP-1 drugs, a class of obesity and diabetes medications whose high costs have limited insurance coverage. Yaccarino emphasized the company’s vision to transform the weight-loss category at a critical moment.

The telehealth sector focused on GLP-1 drugs is growing rapidly but faces increased scrutiny over safety, marketing, and regulatory challenges. Industry experts note Yaccarino’s digital marketing skills will be valuable as the sector shifts toward a direct-to-consumer model.

eMed claims its platform can reduce weight loss program costs by up to 50%, offering live, on-demand care without the need for appointments. The company initially gained traction through at-home COVID-19 testing during the pandemic and later expanded into diagnostics for other illnesses but has since refocused on telehealth services.

Currently, eMed employs between 51 and 200 people.